

ORIGINAL ARTICLE

Fractional Flow Reserve-Guided PCI for Stable Coronary Artery Disease

Bernard De Bruyne, M.D., Ph.D., William F. Fearon, M.D., Nico H.J. Pijls, M.D., Ph.D., Emanuele Barbato, M.D., Ph.D., Pim Tonino, M.D., Ph.D., Zsolt Piroth, M.D., Nikola Jagic, M.D., Sven Mobius-Winckler, M.D., Gilles Riouffol, M.D., Ph.D., Nils Witt, M.D., Ph.D., Petr Kala, M.D., Philip MacCarthy, M.D., Thomas Engström, M.D., Keith Oldroyd, M.D., Kreton Mavromatis, M.D., Ganesh Manoharan, M.D., Peter Verlee, M.D., Ole Frobert, M.D., Nick Curzen, B.M., Ph.D., Jane B. Johnson, R.N., B.S.N., Andreas Limacher, Ph.D., Eveline Nüesch, Ph.D., and Peter Jüni, M.D., for the FAME 2 Trial Investigators*

ABSTRACT

We hypothesized that in patients with stable coronary artery disease and stenosis, The authors' affiliations are listed in the percutaneous coronary intervention (PCI) performed on the basis of the fractional flow reserve (FFR) would be superior to medical therapy.

METHODS

In 1220 patients with stable coronary artery disease, we assessed the FFR in all stenoses that were visible on angiography. Patients who had at least one stenosis with an FFR of 0.80 or less were randomly assigned to undergo FFR-guided PCI plus medical therapy or to receive medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy alone and were included in a registry. The primary end point was a composite of death from any cause, nonfatal myocardial infarction, or urgent revascularization within 2 years.

RESULTS

The rate of the primary end point was significantly lower in the PCI group than in the medical-therapy group (8.1% vs. 19.5%; hazard ratio, 0.39; 95% confidence interval [CI], 0.26 to 0.57; P<0.001). This reduction was driven by a lower rate of urgent revascularization in the PCI group (4.0% vs. 16.3%; hazard ratio, 0.23; 95% CI, 0.14 to 0.38; P<0.001), with no significant between-group differences in the rates of death and myocardial infarction. Urgent revascularizations that were triggered by myocardial infarction or ischemic changes on electrocardiography were less frequent in the PCI group (3.4% vs. 7.0%, P=0.01). In a landmark analysis, the rate of death or myocardial infection from 8 days to 2 years was lower in the PCI group than in the medical-therapy group (4.6% vs. 8.0%, P=0.04). Among registry patients, the rate of the primary end point was 9.0% at 2 years.

In patients with stable coronary artery disease, FFR-guided PCI, as compared with medical therapy alone, improved the outcome. Patients without ischemia had a favorable outcome with medical therapy alone. (Funded by St. Jude Medical; FAME 2 ClinicalTrials.gov number, NCT01132495.)

FAME 2 **Report of the Primary Endpoint**

Clinicaltrials.gov NCT01132495

Appendix. Address reprint requests to Dr. De Bruyne at the Cardiovascular Center Aalst. Moorselbaan 164, B-9300 Aalst. Belgium, or at bernard.de.bruyne@ olvz-aalst.be.

*A complete list of investigators and committee members in the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME 2) trial is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on September 1, 2014, at NEJM.org.

DOI: 10.1056/NEJMoa1408758 Copyright @ 2014 Massachusetts Medical Society

Potential conflicts of interest

Speaker's name: Bernard De Bruyne

☐ I have the following potential conflicts of interest to report:

Research contracts
Consulting
☐ Employment in industry
☐ Stockholder of a healthcare company
☐ Owner of a healthcare company
☐ Other(s)

☐ I do not have any potential conflict of interest

Study Supported by St. Jude Medical


FAME 2 Background

PCI is the preferred treatment in <u>acute</u> coronary syndromes, but has never been shown to reduce 'hard end-points' in <u>stable</u> coronary artery disease.


FAME 2 Objective

To compare the rate of death, myocardial infarction, or urgent revascularization 2 years after contemporary PCI or MT alone in stable CAD


FAME 2 Flow Chart



FAME 2 Primary Outcomes



FAME 2 Death/Myocardial Infarction Landmark Analysis



FAME 2 Summary

- 1. The rate of the composite of death, MI, or urgent revascularization at 2 years in patients with stable CAD treated with FFR-guided PCI with new generation DES was less than half than in patient treated with MT alone.
- 2. Patients in whom the stenoses are not able to induce ischemia (FFR>0.80) are doing well with MT alone.
- 3. Beyond 7 days from randomisation, PCI plus MT significantly reduces the rate of death or MI when compared to MT alone.


CONCLUSION

In patients with stable CAD, PCI is superior to MT provided

- ✓ FFR is used to guide the procedure
- **✓ DES of 2nd generation are implanted**

FAME 2

Urgent revascularisations according to different triggers for the revascularisation



Urgent revascularisation was triggered in > 80% by an MI, by dynamic ST changes, or by resting angina

FAME 2 Symptoms

